Air Sonea (Gen I) has been superseded by wheezo (Gen II) in 2017.
In 2017 (Gen II) breath censor and further development of the app produced the first marketing prototype. Since then further fine tuning of the device and app has continued and I believe, without doubt, will be proven to be the best possible monitoring device for Asthma.
As reported wheezo will be launched in Australia in Q4 and will be used as a springboard for introduction into other countries.
Hope that helps!
Cheers
RSH Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
